Chronic wounds are one of the most costly and least visible burdens in modern healthcare. Conditions such as diabetic foot ulcers, venous leg ulcers and pressure ulcers affect millions of people worldwide, and many are rooted in metabolic disease, poor circulation and diet. They heal slowly, are painful to manage, and conventional care is often fragmented across multiple products, dressings and clinic visits. When a wound fails to close, the consequences escalate quickly, from chronic infection to, in the worst cases, amputation. Yet innovation in wound care has been slow, and most treatments manage the wound rather than actively driving it to heal.
Omeza is a regenerative skin and wound care company built around the healing power of omega-3 fatty acids. Its lead product, the Omeza Collagen Matrix, combines hydrolysed fish collagen with cod liver oil and plant-derived oils to protect the wound bed and support tissue regeneration, working alongside the Omeza Lidocaine Lavage and Omeza Skin Protectant. Together they simplify the episode of care and help wounds close faster, at any site of care from hospital to home. The natural formulation delivers omega 3, 6 and 9 fatty acids, tissue-signalling molecules and vitamins A, C, D and E, all drawn from marine and plant sources. The product bundle was recognised with a Top Innovation in Wound Care award by Wound Management & Prevention.
By using marine and plant-derived nutrition to heal wounds that conventional medicine struggles with, Omeza sits precisely where food and human health meet. Its work reflects Astanor’s conviction that what nature produces, from soil and sea, can help prevent and reverse the chronic conditions that weigh most heavily on human health.
